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INTRODUCTION 
Respiratory syncytial virus (RSV) is the most common
causative agent of lower respiratory tract disease in infants
(1). Bronchiolitis, one of the lower respiratory tract diseases
in infants, is an important obstructive airway disease in pedi-
atric populations. The clinical manifestations of bronchioli-
tis include cough, wheezing, and dyspnea; these symptoms
are similar to those of bronchial asthma and RSV infection,
and can provoke and aggravate bronchial asthma. RSV infec-
tion plays a significant role in inducing recurrent wheezing
and bronchial asthma. More than 50% of bronchiolitis cases
are caused by RSV. Furthermore, as compared to non-RSV
bronchiolitis, RSV bronchiolitis is more prone to develop
into bronchial asthma (1-7). 
The pathogenesis of both bronchial asthma and bronchi-
olitis involves many cytokines and chemokines, such as inter-
leukin (IL)-5 and IL-8, whose levels are regulated following
the activation of normal T cells. They are regulated on acti-
vation normally T-cell expressed and secreted (RANTES),
eotaxin, and MIP 1- (macrophage inflammatory protein)
that cause allergic inflammatory reactions (1, 2, 5, 7-10).
Among these cytokines, RANTES and eotaxin play signifi-
cant roles in inducing chemotaxis and activating eosinophils
that are one of the most important factors in allergic inflam-
mation. Assuming that the clinical manifestations are simi-
lar to those of bronchial asthma and have a high possibility
of developing into bronchial asthma, the immunopathophys-
iology of bronchiolitis can be considered to be similar to that
of bronchial asthma. In addition, similar chemokine and eosi-
nophil activation can also be observed in bronchiolitis.
It has been known that RSV selectively acts on respiratory
epithelial cells in airway diseases such as bronchiolitis and
bronchial asthma. However, since RSV infection promotes
not only local reactions but also systemic manifestations, the
systemic actions of RSV cannot be overlooked. No significant
research data has yet been reported to support this concept. 
In this study, the very important factors involved in the
immunopathophysiology of bronchial asthma such as eosino-
philic cationic protein (ECP), RANTES, and eotaxin were
examined in the nasopharyngeal secretions (NPS) of patients
with bronchiolitis to investigate their possible roles in the
pathophysiology of bronchiolitis. 
MATERIAL AND METHODS
Subjects 
Patients admitted to Kangnam St. Mary’s Hospital from
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Eosinophil Cationic Protein and Chemokines in Nasopharyngeal 
Secretions of Infants with Respiratory Syncytial Virus (RSV) 
Bronchiolitis and Non-RSV Bronchiolitis
Bronchiolitis is a risk factor for the development of childhood asthma. Eosinophilic
inflammation in airways plays an important role in the pathophysiology of both bron-
chiolitis and asthma. To investigate this inflammation, we measured the eosinophil
cationic protein (ECP), regulated on activation normal T-cell expressed and secret-
ed (RANTES) and eotaxin levels in nasopharyngeal secretions (NPS). Twenty-eight
patients with RSV bronchiolitis (RSV group), 11 patients with non-RSV bronchioli-
tis (non-RSV group) and 7 controls were enrolled in this study. ECP, RANTES, and
eotaxin levels were measured by enzyme immunoassays. The ECP level in the
NPS of the RSV group was significantly higher than that in the NPS of the non-RSV
group and controls. RANTES and eotaxin levels in infants with bronchiolitis were
significantly higher than those in the controls, but there was no significant difference
between the RSV and non-RSV groups. In conclusion, with regard to eosinophilic
airway inflammation, as compared with non-RSV bronchiolitis, RSV bronchiolitis
may be more similar to childhood asthma. 
Key Words : Respiratory Syncytial Viruses; Bronchiolitis; Nasopharyngeal Secretion; Body Secretions; Eosino-
phil Cationic Protein; RANTES; Eotaxin; CCL11 chemokine
Received : 3 February 2006
Accepted : 12 June 200638 H.H. Kim, M.H. Lee, J.S. Lee
January to December 2002, with no evidence of bacterial
infections and no specific medical histories were selected as
study groups. The study groups comprised patients initi-
ally diagnosed with bronchiolitis on the basis of the follow-
ing symptoms: mild fever, cough, tachypnea, wheezing due
to chest auscultation, and hyperinflation detected by chest
radiography. Based on the NPS examination, the patients
were divided into two groups; 28 patients with RSV bron-
chiolitis (RSV group) and 11 patients with non-RSV bron-
chiolitis (non-RSV group). The control group comprised 7
patients who were admitted to the hospital for elective oper-
ations without any evidence of respiratory or gastrointesti-
nal infections. All the patient’ parents gave their informed
consent in accordance with a protocol approved by the Ethics
Committee of Kangnam St. Mary’s Hospital, The Catholic
University of Korea.
Sample collection 
NPS was aspirated from the nasal cavities of the patients
using an 8-French aseptic catheter, and collected in a 15-mL
conical tube containing 2 mL of transfer media (gentamicin
50  g/mL, fungizone 500  g/mL, penicillin G 340 U/mL).
The collected nasal secretion samples were transferred to the
laboratory where they were mixed and centrifuged for 5 min
at 1,500 r.p.m.
Detection of RSV in nasopharyngeal secretion
Primary detection of infection with RSV, adenovirus, para-
influenza virus, or influenza virus A and B was made by car-
rying out an indirect immunofluorescence assay (IFA) using
cells obtained from the nasal cavity. To confirm viral infec-
tion, 0.1-0.2 mL of the supernatant was inoculated in 2 sets
of test tubes. The first set contained human epidermal carci-
noma cells (HEp-2, CCL-23; ATCC) that were cultured as a
monolayer in Modified Eagle’s Media (MEM, Life Technolo-
gies GIBCO BRL, Grand Island, NY, U.S.A.) supplement-
ed with 10% fetal calf serum. The second set of test tubes
contained Madin Darby canine kidney cells (MDCK, CCL-
34; ATCC). After inoculation, we cultured the cells in a CO2
incubator at 37℃ and observed them for the development
of any cytopathologic effect for 10 days. If cytopathologic
effects were detected in the HEp-2 cells (RSV, adenovirus)
or MDCK cells (parainfluenza virus, influenza virus A and
B), an indirect immunofluorescence assay against RSV was
performed again to confirm the infection. A part of the naso-
pharyngeal secretion was stored at 70℃, and frozen until the
measurement of chemokine levels. 
For secondary detection, the HEp-2 cells showing cytopa-
thologic effects were scraped from the well, rinsed twice with
phosphate buffered saline (PBS, pH 7.4), placed on 10-hole
slides (10  L/well), and dried. The dried cells were fixed with
acetone at 4℃, mixed with primary antibodies to RSV (Che-
micon International, Temecula, CA, U.S.A.) and adenovirus
(Chemicon International), and incubated at 37℃ for 1 hr.
Primary antibodies to the parainfluenza virus (Chemicon In-
ternational) and influenza viruses A and B (Chemicon Inter-
national) were added to the MDCK cells and incubated at
37℃for 1 hr. 
After the reaction, the cells were washed twice with PBS,
and FITC-conjugated (Fluorescein isothiocyanate, ICN Phar-
maceuticals Inc., OH, U.S.A.) secondary antibodies were
added. Subsequently, the cells were incubated at 37℃ for 1
hr, washed twice with PBS, and dried well; following this,
mineral oil was added to the cells. An immunofluorescence
microscope was used to detect cells that showed definite flu-
orescence; these were considered to be positive for viral infec-
tion. 
Collection of blood 
On the day of admission, the patient’s peripheral blood was
drawn using a vacuum tube containing heparin (Belliver In-
dustrial Estate, Plymouth, U.K.) and sent to a clinical pathol-
ogy laboratory for an eosinophil count. Another small volume
of blood was collected in a blood separation container (Bec-
ton Dickinson Vacutainer SST, Rutherford, NJ, U.S.A.) and
centrifuged at 2,500 r.p.m. for 10 min, and then stored frozen
at -70℃ until required. The total serum IgE level measured
by fluorescent enzyme immunoassay (FEIA, UniCAPTM100,
Pharmacia Diagnostics AB, Uppsala, Sweden) ranged from
500 kU/L to 2,000 kU/L. 
Measuring ECP, RANTES, and eotaxin levels in nasopha-
ryngeal secretions 
After heating the frozen NPS, a quantitative sandwich
enzymatic immunoassay (R&D Systems, Minneapolis, MN,
U.S.A.) was performed to measure the concentration of RA-
NTES and eotaxin. The minimum measurable concentration
was 5 pg/mL. The ECP level that was measured by fluores-
cent enzyme immunoassay (FEIA, UniCAPTM100, Pharma-
cia Diagnostics AB, Uppsala, Sweden) ranged from 2  g/L
to 200  g/L. 
Statistical analysis 
Comparisons were made among the RSV, non-RSV, and
control groups as well as between the bronchiolitis and con-
trol groups by using the Mann-Whitney U test using SPSS
for Windows version 10.0. 
The correlation among ECP, RANTES, and eotaxin levels
in the NPS of the RSV group was analyzed by Spearman’s
rank correlation test, and a p value less than 0.05 was consid-
ered to be statistically significant. RESULTS
Demographic data
There was no significant difference in the age, serum IgE
level, and eosinophil count in the peripheral blood between
the control and bronchiolitis groups. The patients’ ages ranged
from 1 month to 24 months (Table 1). 
Eosinophil cationic protein level in nasopharyngeal secre-
tions 
The ECP level in NPS was significantly higher in both the
RSV (76±70.9 g/L,  p=0.001) and non-RSV groups (26
±32.9 g/L,  p=0.012) when compared to the ECP level of
control group (2.5±0.7  g/L). The ECP level in the NPS
of RSV group was significantly higher than one of non-RSV
group (p=0.033). The ECP level in NPS from the bronchioli-
tis group (61.9±66.2  g/L) was statistically higher than
that of the control group (p=0.0013). This was more promi-
nently observed in the case of RSV bronchiolitis, in which a
significant difference was observed in the ECP levels between
the RSV and non-RSV groups (Fig. 1, Table 2). 
RANTES level in nasopharyngeal secretions 
The RANTES level was significantly elevated in the bron-
chiolitis group (77.5±3.9 pg/mL) compared to that of the
control group (3.9±1.9 pg/mL). There was no significant
difference in RANTES levels between the RSV (89.1±134.3
pg/mL) and non-RSV groups (48.17±70.60 pg/mL). It was
significantly higher in the RSV group than in the control
group (p=0.013) (Fig. 2, Table 2). 
Eotaxin level in nasopharygeal secretions 
The eotaxin level was significantly higher (p=0.010, Fig. 3)
in the bronchiolitis group (60.0±45.4 pg/mL) than in the
control group (22.0±22.9 pg/mL). The increase in eotaxin
levels was more prominent in the RSV group (60.07±47.07
pg/mL) than in the non-RSV group (59.64±43.08 pg/mL)
(p=0.049). However, there was no significant difference in
the eotaxin levels between the RSV and non-RSV groups
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*Data are given as mean±standard deviation (SD) and values were
not different between each group (p>0.05). 
RSV (+), RSV bronchiolitis; RSV (-), non-RSV bronchiolitis.
Bronchiolitis
RSV (+)  RSV (-) 
Control
Number of subjects  7 28 11
Age, mean (month) 7.4  6.3  7.7
Sex (male:female)  0.8:1 1:1 0.6:1
WBC (/ L)* 8,646±2,819 9,869±3,204 12,381±5,782
Eosinophil count (/ L)*  134±88 163±355 173±202
IgE (kU/L)* 14.1±3.1 26.2±31.8 23.0±17.2
Table 1. Population characteristics of the subjects 
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Fig. 1. ECP levels in nasopharyngeal secretion are significantly
different between group (p<0.05). 
RSV (+), RSV bronchiolitis; RSV (-), non-RSV bronchiolitis.
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Fig. 2. RANTES levels in nasopharyngeal secretion of infants with
RSV bronchiolitis are significantly higher than those of controls
(p<0.05). 
RSV (+), RSV bronchiolitis; RSV(-), non-RSV bronchiolitis.
p=0.013
NS
Data are given as mean±SD. 
RSV (+), RSV bronchiolitis group; RSV (-), non-RSV bronchiolitis group.
*p<0.05 vs. control group, 
� p<0.05 vs. control group, 
� p<0.05 vs. non-
RSV bronchiolitis group, 
�p<0.05 vs. control group.
ECP ( g/L)  RANTES (ng/mL) Eotaxin (pg/mL)
Control 2.53±0.65 3.93±1.85 21.97±22.93 
Bronchiolitis 61.89±66.17* 77.52±3.93* 59.95±45.41*
RSV (+) 75.99±70.93
� ,� 89.05±134.27
� 60.07±47.07
�
RSV (-) 26.02±32.90
� 48.17±70.60 59.64±43.08
�
Table 2. The concentration of eosinophil cationic protein (ECP),
Regulated on Activation Normal T-cell Expressed and Secreted
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(Fig. 3, Table 2). 
Correlation among ECP, RANTES, and eotaxin levels in
the nasopharyngeal secretions of infants with RSV bron-
chiolitis 
The ECP levels in NPS from the RSV group appeared to
be more correlated with eotaxin levels (p=0.02, r=0.562) than
with RANTES levels (p=0.0497, r=0.36) (Fig. 4). The RA-
NTES level in NPS from the RSV group was found to be
significantly correlated with that of eotaxin (p=0.039, r=
0.4390) (Fig. 5). 
DISCUSSION
The clinical manifestation of bronchiolitis is similar to that
of bronchial asthma, and RSV infection that causes bronchi-
olitis can induce or aggravate an asthmatic attack and the
symptoms of asthma. Since it is highly likely that RSV bron-
chiolitis may later develop into bronchial asthma, there may
be a high degree of similarity between RSV bronchiolitis and
bronchial asthma with regard to inducing airway inflamma-
tion (1, 11, 12). 
If the clinical symptoms of RSV bronchiolitis are similar
to those of bronchial asthma and if there exists a high possi-
bility of developing bronchial asthma from bronchiolitis, at
least a part of the immunopathophysiology of the two dis-
eases may appear to be similar with regard to eosinophilic
activation in airway inflammatory reactions, RANTES, and
eotaxin secretion during cellular activation in asthma. These
occurrences may also be observed in bronchiolitis, particularly
RSV bronchiolitis. 
ECP, an indicator of eosinophilic activation (13), RANTES,
and eotaxin were significantly higher in the NPS of patients
with bronchiolitis than in the NPS of patients in the control
group. This was more prominently observed in patients with
RSV bronchiolitis. ECP is one of the most potent toxic pro-
teins secreted by eosinophils, and participates in powerful
toxic reactions (8, 11). Furthermore, it is known to act pro-
tectively against parasitic infections and participate in airway
inflammatory diseases such as bronchiolitis caused by RSV
infection (11, 14). In addition, ECP in the nasal secretions of
bronchiolitic children has been extremely useful in predict-
ing the future development of persistent asthma (12, 15). 
From our study, the ECP level was higher in NPS of the
bronchiolitis group than in the control group. This was more
prominently observed in the RSV bronchiolitis group than
in the non-RSV bronchiolitis group. According to Sung et al.
Fig. 4. ECP level in nasopharyngeal secretion of infants with RSV
bronchiolitis show highly correlated with eotaxin level (p=0.02, r=
0.562) than with RANTES level (p=0.0497, r=0.36). 
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Fig. 5. RANTES and eotaxin levels in nasopharyngeal secretion
of infants with RSV bronchiolitis show significant correlation (r=
0.4392, p=0.039). 
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Fig. 3. Eotaxin levels in nasopharyngeal secretion of infants with
RSV bronchiolitis as well as those of infants with non-RSV bronchi-
olitis are significantly higher than those of controls (p<0.05). 
RSV (+), RSV bronchiolitis; RSV (-), non-RSV bronchiolitis.
p=0.049
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(14), the ECP level in the nasal secretions of patients with
lower airway diseases, such as RSV infection and influenza,
was significantly higher in patients with wheezing. Accord-
ing to Oh and coworkers (16), the ECP level in nasal secre-
tions in patients with bronchial asthma, RSV, or influenza
virus-induced bronchiolitis was significantly higher than that
in the control group. In particular, the ECP level in patients
with bronchial asthma was significantly high, yet there were
no significant differences among the different virus groups
of bronchiolitis patients. In our study, we did not differenti-
ate the degree of increase in ECP level among each virus group;
however, a significant difference was observed in the ECP
levels between the RSV and non-RSV bronchiolitis groups.
In summary, the eosinophil count increases in RSV bronchi-
olitis, this is similar to bronchial asthma; however, further
investigation is required to determine the presence of similar
reactions in other respiratory diseases. The significant differ-
ence in ECP levels is attributed more to the localized effect
of RSV on the target tissue rather than to the systemic effect
of RSV. This correlates with the report that performing eosi-
nophil and ECP counts using a patient’s sputum, rather than
peripheral blood, is a more accurate measure of the airway
inflammatory reaction (17, 18). 
RANTES and eotaxin are CC chemokine equivalent. RA-
NTES induces chemotactic activity in eosinophils, basophils,
monocytes and memory T cells (1, 2, 8, 9, 15), while eotaxin
selectively induces chemotactic activity in eosinophils (20,
21). Respiratory viruses, particularly RSV, activate the for-
mation of RANTES in airway epithelial cells (7, 9, 15). 
Eotaxin is produced in endothelial cells, mast cells, fibrob-
lasts, airway epithelial cells, smooth muscle cells, chondro-
cytes, eosinophils, and various other cells. It is activated by
inflammatory cytokines such as IL-1, TNF- , and IFN- in
a manner similar to that of RANTES activation.
RANTES and eotaxin can be assumed to be closely asso-
ciated with the pathophysiology of bronchiolitis, particular-
ly RSV bronchiolitis, since eosinophil plays important role
in the pathophysiology of bronchiolitis. There is also a report
that the production of RANTES differs with the degree of
RSV proliferation and airway epithelial cell infection. There-
fore, the RANTES level in nasal secretions is related to the
severity of RSV bronchiolitis (1, 9). In lower respiratory dis-
eases, local inflammation is caused by the cytopathic effect
of RSV on the airway epithelial cells and the host’s systemic
inflammatory reactions (1). RANTES level in the NPS of
the bronchiolitis group was significantly higher than that of
the control group. This was more prominent in the RSV
group, suggesting that the RANTES level in NPS may be
influenced to a greater extent by RSV. 
According to Olszewska-Pazdrak et al. (7), RSV infection
promotes RANTES production in the airway epithelial cells.
RANTES also promotes eosinophilic entry into the airway;
the eosinophils then produce RANTES following RSV infec-
tion. Therefore, compared to non-RSV bronchiolitis an in-
creased level of RANTES is observed in RSV bronchiolitis;
this is consistent with our experiment. In this study, the RA-
NTES level is significantly higher in RSV bronchiolitis than
in the NPS of patients of the control group. In non-RSV bron-
chiolitis, the RANTES level was higher than that of the con-
trol group; however, the increase was not statistically signif-
icant. 
Compared to the number of reports on RANTES, there
have been few reports on eotaxin in RSV bronchiolitis. In our
study the eotaxin level in NPS from the bronchiolitis group
was increased. However, there was no significant difference
observed between the RSV and non-RSV groups. 
The ECP, RANTES, and eotaxin levels in NPS of the
bronchiolitic group were significantly higher than that in the
control group. In particular, the ECP level was significantly
different between RSV bronchiolitis and non-RSV bronchi-
olitis. When considering reports that the serum ECP is not
significantly increased in RSV bronchiolitis or infant wheez-
ers, NPS may be a more predictable material for measuring
inflammatory reactions in lower airway diseases such as bron-
chiolitis and asthma.
Unlike significant correlations between the levels of ECP,
RANTES, eotaxin in RSV group, the significances between
RSV and non-RSV group are different. One of the reasons
for the different significances, may be that many inflamma-
tory cells including eosinophil and their mediators interact
with complexity in the airway inflammation in each group.
In conclusion, the pathophysiologic mechanism in bron-
chiolitis may be similar to that in childhood asthma with
regard to airway eosinophilic inflammation. In particular, a
few differences were evident between RSV and non-RSV
bronchiolitis. This similarity may be associated with asth-
ma inception later in life due to RSV bronchiolitis. Further
investigation is required on this subject. 
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